{"entity":{"id":"nct04724369","kind":"trial","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","aka":[],"tldr":"A phase 3 trial of 18F-MFBG in neuroblastoma, run by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), now completed.","summary":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma is a phase 3 interventional study registered as NCT04724369 by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), with 43 participants enrolled, started 2021-11-18 and reached its primary completion in 2026-07-30. Interventions recorded: 18F-MFBG.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04724369","url":"https://clinicaltrials.gov/study/NCT04724369"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Registry status on 22 September 2026: Completed (registry record last updated 17 September 2026; primary completion reached 30 July 2026)."],"nct":"NCT04724369","phase":"3","setting":"A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","started":"2021-11-18","startedType":"actual","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04724369/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"}]}}